Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 337

1.

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.

Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM.

Am Heart J. 2018 Sep 29;206:80-93. doi: 10.1016/j.ahj.2018.09.011. [Epub ahead of print]

PMID:
30342298
2.

Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease.

Khariton Y, Patel KK, Chan PS, Pokharel Y, Wang J, Spertus JA, Safley DM, Hiatt WR, Smolderen KG.

Clin Cardiol. 2018 Oct 4. doi: 10.1002/clc.23087. [Epub ahead of print]

3.

Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial.

Baumgartner I, Norgren L, Fowkes FGR, Mulder H, Patel MR, Berger JS, Jones WS, Rockhold FW, Katona BG, Mahaffey K, Hiatt WR; Executive Committee and Investigators of the EUCLID Trial.

J Am Coll Cardiol. 2018 Oct 2;72(14):1563-1572. doi: 10.1016/j.jacc.2018.07.046.

PMID:
30261955
4.

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26.

PMID:
30145946
5.

Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization.

Hess CN, Rogers RK, Wang TY, Fu R, Gundrum J, Allen LaPointe NM, Hiatt WR.

J Am Coll Cardiol. 2018 Aug 28;72(9):999-1011. doi: 10.1016/j.jacc.2018.06.041.

PMID:
30139446
6.

Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators.

Intern Emerg Med. 2018 Aug 3. doi: 10.1007/s11739-018-1922-y. [Epub ahead of print]

PMID:
30076553
7.

Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.

Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Millegård M, Blomster J, Reist C, Hiatt WR, Patel MR, Mahaffey KW; EUCLID Trial Steering Committee and Investigators.

Vasc Med. 2018 Jul 1:1358863X18775594. doi: 10.1177/1358863X18775594. [Epub ahead of print]

PMID:
29992857
8.

Antithrombotic Therapy for Peripheral Artery Disease in 2018.

Hess CN, Hiatt WR.

JAMA. 2018 Jun 12;319(22):2329-2330. doi: 10.1001/jama.2018.5422. Review. No abstract available.

PMID:
29860284
9.

Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).

Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR.

Am Heart J. 2018 May;199:83-91. doi: 10.1016/j.ahj.2018.01.011. Epub 2018 Feb 3.

PMID:
29754671
10.

Behavior-Change Intervention Targeting Physical Function, Walking, and Disability After Dysvascular Amputation: A Randomized Controlled Pilot Trial.

Christiansen CL, Miller MJ, Murray AM, Stephenson RO, Stevens-Lapsley JE, Hiatt WR, Schenkman ML.

Arch Phys Med Rehabil. 2018 Nov;99(11):2160-2167. doi: 10.1016/j.apmr.2018.04.011. Epub 2018 May 7.

PMID:
29746823
11.

Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution.

Rogers RK, Hiatt WR, Patel MR, Shishehbor MH, White R, Khan ND, Bhalla NP, Jones WS, Low Wang CC.

Vasc Med. 2018 Apr 1:1358863X18760996. doi: 10.1177/1358863X18760996. [Epub ahead of print]

PMID:
29629845
12.

Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators.

Intern Emerg Med. 2018 Aug;13(5):651-660. doi: 10.1007/s11739-018-1835-9. Epub 2018 Mar 26. Erratum in: Intern Emerg Med. 2018 Aug 3;:.

PMID:
29582316
13.

Response by Brass and Hiatt to Letter Regarding Article, "Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease".

Brass EP, Hiatt WR.

Circulation. 2018 Mar 20;137(12):1304. doi: 10.1161/CIRCULATIONAHA.117.032707. No abstract available.

PMID:
29555719
14.

Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.

Norgren L, Patel MR, Hiatt WR, Wojdyla DM, Fowkes FGR, Baumgartner I, Mahaffey KW, Berger JS, Jones WS, Katona BG, Held P, Blomster JI, Rockhold FW, Björck M; EUCLID Steering Committee and Investigators.

Eur J Vasc Endovasc Surg. 2018 Jan;55(1):109-117. doi: 10.1016/j.ejvs.2017.11.006. Epub 2017 Dec 20.

PMID:
29273390
16.

PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes.

Hess CN, Low Wang CC, Hiatt WR.

Annu Rev Med. 2018 Jan 29;69:133-145. doi: 10.1146/annurev-med-042716-091351. Epub 2017 Nov 2.

PMID:
29095667
17.

Feasibility of Serial 6-min Walk Tests in Patients with Acute Heart Failure.

Collins SP, Thorn M, Nowak RM, Levy PD, Fermann GJ, Hiestand BC, Cowart TD, Venuti RP, Hiatt WR, Foo S, Pang PS.

J Clin Med. 2017 Sep 11;6(9). pii: E84. doi: 10.3390/jcm6090084.

18.

Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease.

Brass EP, Hiatt WR.

Circulation. 2017 Aug 29;136(9):785-786. doi: 10.1161/CIRCULATIONAHA.117.028888. No abstract available.

PMID:
28847795
19.

A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative.

Hess CN, Norgren L, Ansel GM, Capell WH, Fletcher JP, Fowkes FGR, Gottsäter A, Hitos K, Jaff MR, Nordanstig J, Hiatt WR.

Circulation. 2017 Jun 20;135(25):2534-2555. doi: 10.1161/CIRCULATIONAHA.117.024469. Review. Erratum in: Circulation. 2017 Nov 7;136(19):e347.

PMID:
28630267
20.

Response by Jones et al to Letter Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease".

Jones WS, Hiatt WR, Patel MR.

Circulation. 2017 Jun 6;135(23):e1109-e1110. doi: 10.1161/CIRCULATIONAHA.117.028199. No abstract available.

PMID:
28584036

Supplemental Content

Loading ...
Support Center